Home » Newsletters » BioWorld Science

BioWorld Science

May 24, 2016

View Archived Issues

Mutations in ZAS may be associated with congenital myopathy

Mersana's XMT-1536 targets tumors expressing sodium-dependent phosphate transport protein 2B

TRIP-13 identified as a therapeutic target in hepatocellular carcinoma

Vasohibin-1 shows promise as a therapeutic target for diabetic erectile dysfunction

Ionis and MD Anderson form strategic alliance to discover and develop novel cancer therapeutics

Darzalex receives European conditional marketing authorization for multiple myeloma

Positive topline results from a first-in-human trial of broad spectrum MVA-BN RSV vaccine

Catabasis' SREBP inhibitors show potential for NASH

Merck & Co. patent orexin receptor antagonists

ETHZ, Roche and Universität Zürich disclose CB2 receptor ligands

ECUST and SIMM report dipeptidyl peptidase IV inhibitors

Enanta Pharmaceuticals discloses farnesoid X receptor agonists

IOmet Pharma divulges indoleamine and tryptophan dioxygenase inhibitors

Bayer Schering Pharma announces t-PA inhibitors

New studies support utility of GastroPanel to predict stomach cancer risk

Advanced Accelerator Applications scales up Lutathera production

Survival benefit with Pentaglobin in severe infections caused by multidrug-resistant bacteria

Onoclys BioPharma announces licensing developments

FDA awards fast track designation for AEB-1102 in hyperargininemia

Boehringer Ingelheim and Biomed X establish a global research team

Avastin approved in Japan for cervical cancer

Phase III trial results presented for alirocumab in Japan

Alimera reports real world data on Iluvien in patients with DME

Exelixis reports phase II results for cabozantinib

Interim phase II data for bardoxolone methyl show improvement in renal function

Arbor Pharmaceuticals set to acquire XenoPort

ZVex/mIL12 shows promising antitumor effect in vivo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...